Cortexyme, Inc. (CRTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
CRTX Stock Price Chart Interactive Chart >
CRTX Price/Volume Stats
| Current price | $6.24 | 52-week high | $121.98 |
| Prev. close | $9.06 | 52-week low | $5.60 |
| Day low | $5.60 | Volume | 2,504,972 |
| Day high | $6.64 | Avg. volume | 820,173 |
| 50-day MA | $12.12 | Dividend yield | N/A |
| 200-day MA | $47.94 | Market Cap | 186.44M |
Cortexyme, Inc. (CRTX) Company Bio
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases.
Latest CRTX News From Around the Web
Below are the latest news stories about Cortexyme Inc that investors may wish to consider to help them evaluate CRTX as an investment opportunity.
Parkinson''s Disease Pipeline Offers Promising New Options for Treatment | DelveInsightLos Angeles, USA, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Parkinson''s Disease Pipeline Offers Promising New Options for Treatment | DelveInsight DelveInsight''s "Parkinson''s Disease Pipeline Insight" report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Parkinson''s Disease pipeline landscapes. The report comprises Parkinson''s Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Parkinson''s Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Parkinson''s Disease pipeline products. Some of the key takeaways from the Parkinson''s Disease Pipeline Report Major Parkinson''s Disease companies such as Cerevel Therapeutics, Ab... |
Why Cortexyme Stock Imploded in 2021The clinical-stage drugmaker's shares imploded last year in response to the failure of its lead Alzheimer's disease candidate atuzaginstat in a combined phase 2/3 study. Specifically, atuzaginstat reportedly missed both of its co-primary endpoints in the phase 2/3 Gain trial as a treatment for mild to moderate forms of Alzheimer's disease. Since announcing these disappointing trial results late last year, Cortexyme has said that it plans to trial the drug yet again. |
3 Most-Shorted Stocks at 52-Week Lows to BuyIn a market made up of stocks, these three most-shorted stocks look poised to deliver a much happier 2022 to bullish investors. |
Do Institutions Own Cortexyme, Inc. (NASDAQ:CRTX) Shares?If you want to know who really controls Cortexyme, Inc. ( NASDAQ:CRTX ), then you'll have to look at the makeup of its... |
Wall Streets Take On Cortexyme Inc. (NASDAQ: CRTX) Stock.Cortexyme Inc. (NASDAQ:CRTX) traded at $12.81 at close of the session on Tuesday, 12/21/21, made an upward move of 2.81% on its previous days price. Looking at the stock we see that its previous close was $12.46 and the beta (5Y monthly) reads 0.75 with the days price range being $12.19 $13.179. In terms Wall Streets Take On Cortexyme Inc. (NASDAQ: CRTX) Stock. Read More » |
CRTX Price Returns
| 1-mo | -50.12% |
| 3-mo | -56.24% |
| 6-mo | -88.96% |
| 1-year | -83.30% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -50.55% |
| 2021 | -54.57% |
| 2020 | -50.52% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...